TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11568992

Group type: EXPERIMENTAL
Intervention: eNO measurement in mild intermittent asthmatic children (5.6 +/- 0.4 ppb)
Number of subjects: 84

Group type: COMPARATOR
Intervention: eNO measurement
Number of subjects: 84
Study: 9442542

Group type: EXPERIMENTAL
Intervention: Scavenging at 45 L/min evacuation rate
Number of subjects: 30
Study: 8179790

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study: 3067809

Group type: EXPERIMENTAL
Intervention: Fencamfamine 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fencamfamine 50 mg
Number of subjects: 6
Study: 31948355

Group type: EXPERIMENTAL
Intervention: SCAIL score (symptomatic carotid atheroma inflammation lumen‐stenosis)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SCAIL score
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SCAIL score after positron emission tomography-imaging
Number of subjects: 196

Group type: COMPARATOR
Intervention: SCAIL score vs stenosis severity
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: SCAIL score in mild or moderate stenosis
Number of subjects: 196
Study: 30206342

Group type: EXPERIMENTAL
Intervention: Soymilk for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Matched controls (N=10)
Number of subjects: 10
Study: 27316632

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study: 25428655

Group type: EXPERIMENTAL
Intervention: Direct suggestion
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indirect suggestion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (non-suggestive)
Number of subjects: 31
Study: 24351501

Group type: EXPERIMENTAL
Intervention: Antidepressants (adequate dose for at least 6 weeks)
Number of subjects: 2439
Study: 20602498

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 0
Study: 18443395

Group type: EXPERIMENTAL
Intervention: Aqueous nasal spray 100 microg twice daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nasal drop preparation 400 microg once daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nasal drop preparation 400 microg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 16788316

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 40
Study: 12669896

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 10913928

Group type: EXPERIMENTAL
Intervention: Cyclical hPTH(1-34) therapy (50 microg/day for 28 days in 3-month cycles)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (untreated osteoporotic patients, n = 15)
Number of subjects: 29
Study: 8933239

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bisoprolol (NYHA class III)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem (NYHA class III)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bisoprolol (NYHA class IV)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem (NYHA class IV)
Number of subjects: 18
Study: 1417010

Group type: EXPERIMENTAL
Intervention: Tegafur suppository preoperatively + tegafur oral preparation postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tegafur suppository preoperatively + UFT oral preparation postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegafur oral preparation postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative tegafur administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dukes B patients with preoperative tegafur administration
Number of subjects: 0
Study: 3893024

Group type: EXPERIMENTAL
Intervention: 1% Butoconazole nitrate (BN) vaginal cream
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 2% Butoconazole nitrate (BN) vaginal cream
Number of subjects: 130

Group type: COMPARATOR
Intervention: 2% Miconazole nitrate (MN) vaginal cream
Number of subjects: 130
Study: 31272493

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (maximum dose of 2 × 3 ml)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline placebo (maximum dose 2 × 5 ml)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane
Number of subjects: 110
Study: 30587151

Group type: COMPARATOR
Intervention: 3-month cognitive training program, once per week, consisting of multi-domain and ecological cognitive exercises in small homogenous groups.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive control group (no specific intervention details provided).
Number of subjects: 0
Study: 26329381

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg/day for 35 days with anodal tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 20 mg/day for 35 days with cathodal tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) with dextromethorphan (150 mg) and anodal/cathodal tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC) medication with anodal or cathodal tDCS
Number of subjects: 12
Study: 24629063

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention with four group sessions and home exercises three times a week, with weekly telephone follow-up during eight weeks without group sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 22032832

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 42
Study: 20605552

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 80

Group type: COMPARATOR
Intervention: No physical examination (PE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and light massage control
Number of subjects: 80
Study: 17765899

Group type: EXPERIMENTAL
Intervention: Surgical interventions for fistula repair
Number of subjects: 0
Study: 16140677

Group type: EXPERIMENTAL
Intervention: Pump On (PO) - 50% of the basal rate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pump Off (PF)
Number of subjects: 10
Study: 11854632

Group type: EXPERIMENTAL
Intervention: Postnatal replacement of estradiol and progesterone for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nontreated infants
Number of subjects: 30
Study: 9883100

Group type: EXPERIMENTAL
Intervention: Dangerous situations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Careless behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of good luck
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luck
Number of subjects: 0
Study: 7608436

Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU) before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU) before thrombolytic treatment with saruplase
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo before thrombolytic treatment with saruplase
Number of subjects: 118
Study: 2789272

Group type: COMPARATOR
Intervention: Fluorouracil (5‐FU) alone (arm A)
Number of subjects: 265

Group type: COMPARATOR
Intervention: High‐dose leucovorin plus 5‐FU (arm B)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Sequential methotrexate, 5‐FU, and leucovorin (arm C)
Number of subjects: 265
Study: 342557

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (6 sessions of verbal self-instructions via modeling with response-cost contingent upon errors)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (similar training without specific treatment)
Number of subjects: 20
Study: 30711698

Group type: EXPERIMENTAL
Intervention: 2-dose HPV vaccine
Number of subjects: 1515

Group type: COMPARATOR
Intervention: 3-dose HPV vaccine
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 1515
Study: 28290191

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 28
Study: 26121076

Group type: EXPERIMENTAL
Intervention: Thin-wall introducer needle technique
Number of subjects: 266

Group type: COMPARATOR
Intervention: Cannula-over-needle technique
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 266
Study: 23899172

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21742102

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study: 19958521

Group type: EXPERIMENTAL
Intervention: Anatibant (low, medium, or high dose)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Anatibant (any dose)
Number of subjects: 228
Study: 16430668

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (trigger at 8 g/dl)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (trigger at 10 g/dl)
Number of subjects: 260
Study: 15582838

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) - 1200 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Phenytoin (PHT) - 360 mg
Number of subjects: 32
Study: 10651210

Group type: EXPERIMENTAL
Intervention: Cibenzoline 25 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cibenzoline 50 mg/day
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cibenzoline (25 and 50 mg/day)
Number of subjects: 8
Study: 9078539

Group type: EXPERIMENTAL
Intervention: PTHrP139, PTHrP173, PTHrP141 variants
Number of subjects: 0
Study: 8450580

Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHAP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (100 g polyglucose, Polycose)
Number of subjects: 18
Study: 2945499

Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg loratadine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg loratadine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CTM) 12 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All doses of loratadine
Number of subjects: 60
Study: 3041936

Group type: EXPERIMENTAL
Intervention: Carteolol (2.5 to 5.0 mg/d for an average of 328 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 30741439

Group type: EXPERIMENTAL
Intervention: PEP uP
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study: 30760406

Group type: EXPERIMENTAL
Intervention: TKIs treatment (first-line)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Detection of T790M mutations using ddPCR
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: De novo T790M mutation presence
Number of subjects: 61
Study: 28697773

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment for 5 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 44
Study: 25040321

Group type: EXPERIMENTAL
Intervention: Propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4.
Number of subjects: 90

Group type: COMPARATOR
Intervention: 6 mg of sumatriptan subcutaneously
Number of subjects: 90
Study: 23826887

Group type: EXPERIMENTAL
Intervention: Tailored interventions (peer group supervision and individualised telephone consultations)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Self-rating scale for measuring depressive and anxiety symptoms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Better patient care
Number of subjects: 14
Study: 22186117

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 103
Study: 19097665

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg once daily
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 530
Study: 16817738

Group type: EXPERIMENTAL
Intervention: 75 microg of rhTSH, IM or IV
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1 unit of bTSH, IM
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 75 microg of rhTSH, IV
Number of subjects: 38
Study: 12766621

Group type: EXPERIMENTAL
Intervention: 1.32 ml of 95% alcohol per kilogram of body weight, mixed with orange juice
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 10860330

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser system
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional air turbine/bur dental surgery
Number of subjects: 67
Study: 9356283

Group type: EXPERIMENTAL
Intervention: Olean potato chips (2 oz)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Triglyceride potato chips (2 oz)
Number of subjects: 57
Study: 8482086

Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin as replacement fluid
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Plasma exchange with fresh frozen plasma as replacement fluid
Number of subjects: 220

Group type: COMPARATOR
Intervention: Plasma exchange (both albumin and fresh frozen plasma)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pre-plasma exchange hemoglobin level
Number of subjects: 220
Study: 3514368

Group type: EXPERIMENTAL
Intervention: 0.5 mg of PGE2 in 2.5 ml of Triacetin gel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of PGE2 gel with conventional oxytocin induction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (conventional induction)
Number of subjects: 80
Study: 29490986

Group type: EXPERIMENTAL
Intervention: Buparlisib plus paclitaxel
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 158
Study: 27645244

Group type: EXPERIMENTAL
Intervention: Narlaprevir (NVR) 200 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Narlaprevir (NVR) 100 mg with Ritonavir (RTV) 100 mg
Number of subjects: 32
Study: 25170231

Group type: EXPERIMENTAL
Intervention: Tandospirone (10 mg thrice daily) and pinaverium (50 mg thrice daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pinaverium (50 mg thrice daily) and placebo
Number of subjects: 200
Study: 23697514

Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 53439

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 53439
Study: 19778341

Group type: EXPERIMENTAL
Intervention: Study brochure addressing common donor concerns and suggesting specific coping strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood center brochure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 0
Study: 18096834

Group type: EXPERIMENTAL
Intervention: Comprehensive stroke unit
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Early supported discharge service
Number of subjects: 489
Study: 16632762

Group type: EXPERIMENTAL
Intervention: Dietary counseling sessions (2 sessions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Current standard care
Number of subjects: 58
Study: 12357161

Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 143

Group type: COMPARATOR
Intervention: 2 g acetaminophen
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 2 g acetaminophen and 50 mg rofecoxib
Number of subjects: 143

Group type: COMPARATOR
Intervention: 500 mg vitamin C (placebo)
Number of subjects: 143
Study: 10204818

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (60 mg twice daily) for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: B vitamin complex (control group)
Number of subjects: 59
Study: 7481551

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha
Number of subjects: 37
Study: 2182300

Group type: EXPERIMENTAL
Intervention: Nebulized ketanserin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6446424

Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of dehydroepiandrosterone sulphate (DHEA-S) (100-200 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous injection of dehydroepiandrosterone sulphate (DHEA-S) (100 mg)
Number of subjects: 26
Study: 31897841

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Appendicectomy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 113

Group type: COMPARATOR
Intervention: Randomisation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Blinding
Number of subjects: 113

Group type: COMPARATOR
Intervention: Research participation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Perception of research risk
Number of subjects: 113

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 113
Study: 29091327

Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐2a add‐on therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: TDF alone (NA group)
Number of subjects: 30
Study: 26760456

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SAD
Number of subjects: 135

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 135
Study: 24699298

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 187
Study: 22145572

Group type: EXPERIMENTAL
Intervention: Intracorporeal knotting
Number of subjects: 107

Group type: COMPARATOR
Intervention: Metal endoclip application
Number of subjects: 107
Study: 20390813

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 579

Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 579
Study: 17389535

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen testing (PSA)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Decision-making control by physicians
Number of subjects: 432
Study: 16135583

Group type: EXPERIMENTAL
Intervention: Intrauterine 5‐mL 2% lidocaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 66
Study: 12042267

Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 300 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of oral desogestrel with depot testosterone
Number of subjects: 66
Study: 9543120

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.3 mg/kg x week, mean duration = 41 months)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 94
Study: 8304654

Group type: EXPERIMENTAL
Intervention: High-dose oral acyclovir (800 mg four times daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Preemptive, short-course ganciclovir therapy (5 mg/kg intravenously twice daily for 7 days if CMV shedding occurred)
Number of subjects: 47
Study: 2729815

Group type: EXPERIMENTAL
Intervention: lyophilized collagen pads as adjunctive treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: control group
Number of subjects: 20
Study: 29247643

Group type: EXPERIMENTAL
Intervention: LFS‐01 (sulforaphene) treatment
Number of subjects: 0
Study: 29267760

Group type: EXPERIMENTAL
Intervention: Payment scheme by performance (budget support agreement)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sample (areas without budget support agreements)
Number of subjects: 0
Study: 25736524

Group type: EXPERIMENTAL
Intervention: Pagibaximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23073723

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg/day
Number of subjects: 100
Study: 21282192

Group type: EXPERIMENTAL
Intervention: DDMM (2 doses of DNA followed by 2 doses of rMVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMM (1 dose of DNA followed by 2 doses of rMVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMM (3 doses of rMVA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1/10th-dose DDMM regimen
Number of subjects: 0
Study: 19672930

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (operation within 72 h of admission)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional management (elective cholecystectomy 3 months later)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 72
Study: 17109579

Group type: EXPERIMENTAL
Intervention: Sublingually delivered vitamin B complex
Number of subjects: 41

Group type: COMPARATOR
Intervention: Orally delivered vitamin B complex
Number of subjects: 41
Study: 15080848

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa IU/kg/day for 14 days followed by 4500 anti‐Xa IU/day for 28 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once daily for up to 42 days
Number of subjects: 100